Optimizing Anti-EGFR Therapy in Colorectal Cancer

被引：8

作者：

Salazar, Ramon ^{[1
]}

Ciardiello, Fortunato ^{[2
]}

机构：

[1] Univ Barcelona, Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Dept Med Oncol, Barcelona, Spain

[2] Univ Naples 2, Dipartimento Med Chirurg Internist Clin & Sperime, Naples, Italy

来源：

CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 24期

关键词：

PLUS CETUXIMAB; RAS MUTATIONS; KRAS STATUS; RESISTANCE;

D O I：

10.1158/1078-0432.CCR-15-1768

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment with anti-EGFR monoclonal antibodies has been successfully integrated in the continuum of care for metastatic colorectal cancer. The major challenge is the identification of patients who would benefit from treatment. Currently, the best predictor of efficacy is the absence of mutations in KRAS and NRAS genes. (C)2015 AACR.

引用

页码：5415 / 5416

页数：2

共 50 条

[1] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, Ben
Wang, Lu
Qiu, Hong
Zhang, Mingsheng
Sun, Li
Peng, Ping
Yu, Qianqian
Yuan, Xianglin
[J]. ONCOTARGET, 2017, 8 (03) : 3980 - 4000
[2] Markers of resistance to anti-EGFR therapy in colorectal cancer
Shaib, Walid
Mahajan, Reena
El-Rayes, Bassel
[J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (03) : 308 - 318
[3] Anti-EGFR therapy in first-line colorectal cancer
Lamas, Maria J.
Duran, Goretti
Gallardo, Elena
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1499 - 1503
[4] Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
Yang, Jiao
Li, Shuting
Wang, Biyuan
Wu, Yinying
Chen, Zheling
Lv, Meng
Lin, Yayun
Yang, Jin
[J]. TUMOR BIOLOGY, 2016, 37 (09) : 11645 - 11655
[5] Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
Martins, Marta
Mansinho, Andre
Cruz-Duarte, Raquel
Martins, Soraia Lobo
Costa, Luis
[J]. TARGETED THERAPY OF COLORECTAL CANCER SUBTYPES, 2018, 1110 : 113 - 131
[6] Optimizing Anti-EGFR Strategies in Cancer Treatment
Toschi, Luca
Finocchiaro, Giovanna
Garassino, Isabella
De Vincenzo, Fabio
Campagnoli, Elisabetta
Ceresoli, Giovanni Luca
Cavina, Raffaele
Zucali, Paolo Andrea
Santoro, Armando
Cappuzzo, Federico
[J]. CURRENT CANCER THERAPY REVIEWS, 2007, 3 (04) : 267 - 275
[7] Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
Lo Nigro, Cristiana
Ricci, Vincenzo
Vivenza, Daniela
Granetto, Cristina
Fabozzi, Teresa
Miraglio, Emanuela
Merlano, Marco C.
[J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (30) : 6944 - 6954
[8] Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient
Meriggi, F.
Di Biasi, B.
Abeni, C.
Zaniboni, A.
[J]. CURRENT DRUG TARGETS, 2009, 10 (10) : 1033 - 1040
[9] MicroRNAs and response to anti-EGFR therapy in metastatic colorectal cancer.
Blanco-Calvo, Moises
Haz-Conde, Mar
Rodriguez-Rigueiro, Teresa
Figueroa, Angelica
Reboredo, Margarita
Medina Villaamil, Vanessa
Lorenzo-Patino, Maria J.
Arnal, Francisco
Anton-Aparicio, Luis
Alonso-Jaudenes Curbera, Guillermo
Valladares-Ayerbes, Manuel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[10] Telomere length: A novel biomarker for anti-EGFR therapy in colorectal cancer
Augustine, Titto A.
Baig, Mahadi A.
Mariadason, John M.
Maitra, Radhashree
Goel, Sanjay
[J]. CANCER RESEARCH, 2014, 74 (19)

← 1 2 3 4 5 →